SCHEMBL1109945

SCHEMBL1109945

CCCCCCCCCCCCCCCCCCCCCCCC(=O)NCCO

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SELP P16109 1/20 0.75
CNR1 P21554 3/20 0.73
ALDH1A1 P00352 3/20 0.73
HPGD P15428 2/20 0.73
TRPV1 Q8NER1 2/20 0.73
MEN1 O00255 2/20 0.73
BLM P54132 2/20 0.73
KMT2A Q03164 2/20 0.73
MAPT P10636 1/20 0.73
ALOX12 P18054 1/20 0.73
TDP1 Q9NUW8 1/20 0.73
NAAA Q02083 1/20 0.71
FAAH O00519 5/20 0.69
DNM1 Q05193 1/20 0.68
TRPM8 Q7Z2W7 1/20 0.65
KCNK3 O14649 1/20 0.65
CNR2 P34972 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Palmidrol SCHEMBL120518 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL7858023 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL679082 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL12972842 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL7942314 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL308261 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL308683 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL9425227 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL21357244 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1
SCHEMBL232840 1.00 SELP (0.75) SELPCNR1ALDH1A1HPGDTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014065-A1 PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF Dewey Beauty LLC (US) 2026-01-15 US claimed
US-20250073255-A1 USE OF FA-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) 2025-03-06 US claimed
EP-4378921-A1 USE OF FA-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) 2024-06-05 EP claimed
US-20220290200-A1 GENETICALLY MODIFIED HOST CELLS PRODUCING GLYCOSYLATED CANNABINOIDS OCTARINE BIO IVS (DK) 2022-09-15 US claimed
EP-3976769-A1 GENETICALLY MODIFIED HOST CELLS PRODUCING GLYCOSYLATED CANNABINOIDS Octarine Bio IVS (DK) 2022-04-06 EP claimed
US-20260014065-A1 PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF Dewey Beauty LLC (US) 2026-01-15 US disclosed
US-20250361537-A1 Novel Systems, Methods, And Compositions For The Glycosylation Of Cannabinoid Compounds TRAIT BIOSCIENCES INC (US) 2025-11-27 US disclosed
US-12465628-B2 Cannabinoid carrier compositions having enhance pharmacokinetic properties and methods of use thereof DESERT HARVEST, INC. (US) 2025-11-11 US disclosed
US-12397061-B2 Systems, methods, and compositions for the generation of water-soluble cannabinoids utilizing fatty-acid binding proteins and fatty-acid binding-like proteins as cannabinoid-carriers TRAIT BIOSCIENCES, INC. (US) 2025-08-26 US disclosed
US-12378586-B2 Systems, methods, and compositions for the glycosylation of cannabinoid compounds TRAIT BIOSCIENCES, INC. (US) 2025-08-05 US disclosed
US-20250073255-A1 USE OF FA-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) 2025-03-06 US disclosed
US-20240226075-A1 CANNABIS PRODUCTION SYSTEMS AND METHODS INSECTERGY US LLC 2024-07-11 US disclosed
US-8592117-B2 Toner and developer RICOH COMPANY, LTD. (JP) 2013-11-26 US disclosed
US-20120189951-A1 TONER AND DEVELOPER RICOH COMPANY, LTD. (JP) 2012-07-26 US disclosed
US-8227164-B2 Toner, and developer, developer container, process cartridge, image forming apparatus and image forming method using the toner RICOH COMPANY, LIMITED (JP) 2012-07-24 US disclosed
US-20110076607-A1 TONER, DEVELOPER, TONER ACCOMMODATING CONTAINER, PROCESS CARTRIDGE AND IMAGE FORMING METHOD RICOH COMPANY, LTD. (JP) 2011-03-31 US disclosed
EP-2296044-A1 Toner, and developer, developer container, process cartridge, image forming apparatus and image forming method using the toner Ricoh Company, Ltd. (JP) 2011-03-16 EP disclosed
EP-2279456-A1 TONER, DEVELOPER, TONER ACCOMMODATING CONTAINER, PROCESS CARTRIDGE AND IMAGE FORMING METHOD Ricoh Company, Ltd. (JP) 2011-02-02 EP disclosed
US-20100310980-A1 TONER, AND DEVELOPER, DEVELOPER CONTAINER, PROCESS CARTRIDGE, IMAGE FORMING APPARATUS AND IMAGE FORMING METHOD USING THE TONER RICOH COMPANY LIMITED (JP) 2010-12-09 US disclosed
WO-2009142338-A1 TONER, DEVELOPER, TONER ACCOMMODATING CONTAINER, PROCESS CARTRIDGE AND IMAGE FORMING METHOD RICOH COMPANY, LTD. (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250073255-A1 USE OF FA-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT FABP2, FABP1, FASN SELP 3547/4885CNR1 3695/4885ALDH1A1 3025/4885
US-20240226075-A1 CANNABIS PRODUCTION SYSTEMS AND METHODS CNR2, CNR1, CDIPT SELP 4473/4885CNR1 2/4885ALDH1A1 4844/4885
US-20260014065-A1 PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF DHCR24, CNR2, DSG1 SELP 4850/4885CNR1 6/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.